Chào mừng trở lại
Tham gia Cointime
Đăng nhập với email
Đăng nhập với
Đăng ký
Auris Medical
About
Auris Medical develops novel pharmaceutical therapies to prevent and treat severe inner ear disorders.
- Basel,Basel-Stadt,Switzerland
- 11 - 50
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $12.50M
- Industries
- Health Care,Pharmaceutical,Therapeutics
- Founded date
- Apr 1, 2003
- Number Of Employee
- 11 - 50
- Operating Status
- Active
- Stock Symbol
- fra:2RA1
- Legal Name
- Auris Medical Holding AG
They at Auris Medical are dedicated to developing novel pharmaceutical therapies to protect hearing, silence tinnitus and restore balance.Auris Medical is the leading pioneer in the emerging field of therapies for neurotologic disorders affecting the inner ear. They have two projects in advanced clinical development, Keyzilen® for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. In addition, they have AM-125 in early clinical development for the treatment of vertigo.They have additional projects under development and are further strengthening their pipeline through collaborations with leading academic institutions in this field.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 19, 2016 | Post-IPO Debt | $12.50M | 1 | — | — | Detail |
| Nov 7, 2014 | IPO | — | — | — | — | Detail |
| Apr 16, 2013 | Series C | Fr47.10M | 2 |
Sofinnova Investments
Sofinnova Partners
|
— | Detail |
| Feb 15, 2008 | Series B | $10.08M | 3 | — | — | Detail |
| Dec 1, 2007 | Series A | — | 1 |
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Sofinnova Investments
|
Yes | Series C |
|
Sofinnova Partners
|
Yes | Series C |
Hercules Capital
|
— | Post-IPO Debt |
|
|
— | Series B |
|
|
— | Series B |
Lacuna
|
— | Series B |
Employee Profiles
Acquisition
Auris Medical has acquired 1 organizations. Their most recent acquisition was Trasir Therapeutics on Jun 3, 2021. They acquired Trasir Therapeutics for 0.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Jun 3, 2021
|
Therapeutics | acquisition | — | Detail |
